Failure of the Republicans to repeal Obamacare last Friday sent the markets tumbling to open sharply lower with the Dow plunging 126 points to 20,470. Nasdaq fell 23 points to 5,804.
On the upside
Cellect Biotechnology (Nasdaq: APOP) announced the first successful stem cell transplant procedure using its ApoGraft technology in a Phase I/II clinical trial.
Impax Laboratories (Nasdaq: IPXL) named Paul M. Bisaro to the position of president and chief executive officer.
Weatherford International (NYSE: WFT) formed a joint venture with Schlumberger (NYSE: SLB) to develop unconventional resource plays in the United States and Canada land markets.
On the downside
Foamix Pharmaceuticals (Nasdaq: FOMX) reported disappointing results from two Phase 3 clinical trials investigating FMX101 to treat moderate to severe acne.
G-III Apparel Group (Nasdaq: GIII) fell to a greater than expected loss for the fourth quarter.
Investors locked in profits on Zais Group Holdings (Nasdaq: ZAIS).
In the broad market, declining issues outpaced advancers by a margin of more than 3 to 1 on both the NYSE and on Nasdaq. The broader S&P 500 index fell 12 points to 2,331. Bitcoin soared $65 to $1022.
